My last pick gave everyone here @ Small Cap Firm a chance to rake in up to +33pct in profits!
Did you not make any profits because you decided to sit on the sidelines? If you did don’t worry, because it’s time to turn your full attention to my newest trading idea – STLT!
Judging from Monday’s trading session, STLT has clearly began the upward swing savvy traders crave for. Hurry up and start your research before a potential run takes place.
STLT Recently Ramped Up Efforts To Fight Zika and Spinal Muscular Atrophy!
STLT could Provide Traders With Significant Short-Term Gains on Tuesday 12/06!
Based on the fact; The 20 MA is $0.7742, currently above current valuation, opening the door for short-term upside of up to +33pct.
I’m very bullish, for sure as you can see. But here’s one of the main reasons why: ZIKA VIRUS.
I know I say this all the time but… Please remember I’m not a licensed financial advisor.
Three months ago STLT entered into a Sponsored Research Agreement with Florida State University to support research directed by FSU professor Hengli Tang aimed at developing safe and effective drugs to treat patients infected with Zika virus. Read the full breaking development here: http://finance.yahoo.com/news/spotlight-innovation-inc-joins-battle-123000613.html
As catalysts go, this ZIKA-RELATED news is a major one!
But that’s not it… SERIOUSLY.
On October 6th STLT announced that it has established subsidiary Caretta Therapeutics, and that the subsidiary has entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize products derived from snake venom that may provide analgesic relief from moderate to severe chronic pain. Under the terms of the agreement, Dr. Reid has agreed to grant an exclusive, worldwide license to Caretta Therapeutics to develop, manufacture and sell the products.
Caretta Therapeutics intends to begin manufacturing its first products by late 2016 and to begin commercial distribution of over-the-counter formulations beginning in 2017.
STLT has also been getting attention ever since they announced on October 19th that it has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA).
SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Synthesis and early preclinical testing of STL-182 was accomplished through a research collaboration between Professors Elliot Androphy of Indiana University School of Medicine and Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women’s Hospital.
On November 4th STLT announced that the United States Patent and Trademark Office issued to the Company’s subsidiary Celtic Biotech Iowa U.S. Patent No. 9,345,751, entitled “Crotalus Durissus Terrificus Venom Administration for Cancer Treatment.”
The patented invention relates to compositions isolated from rattlesnake venom (“Crotoxin”) and methods for intravenous administration of Crotoxin to cancer patients.
STLT’s therapeutic product for the treatment of cancer “Crotoxin” is Making Serious FORWARD PROGRESS!
On November 10th STLT announced that its subsidiary Celtic Biotech Iowa has received approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to commence Part 2 of its Phase I dose escalation safety study, Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration. The ANSM, a healthcare regulatory agency, acts on behalf of the French government to ensure patient safety. The clinical study will be conducted at Pitié-Salpêtrière Hospital in Paris. Noted French oncologist David Khayat, MD, PhD, FASCO, is the Principal Investigator.
Mr. Cristopher Grunewald, Spotlight Innovation’s President and Chief Executive Officer, said, “We invested significant time and effort to advance our treatment paradigm using the results of Part 1. We are very pleased that our Part 2 protocol was accepted and approved by ANSM. This marks a significant milestone for Crotoxin as it enters the next stage of clinical testing.”
And here is their most recent corporate development… THE NEWS JUST KEEPS COMING! We rarely see companies trading on the OTCQB with so much going on. This company is definitely one to add to your radar immediately.
Just on November 30th STLT announced that it has made a strategic investment in Solx, Inc., a Massachusetts-based, privately-held medical device company. Principally backed by MVM Life Science Partners, a leading global life science venture capital firm, Solx develops innovative surgical technologies that treat glaucoma and preserve vision.
Mr. Kevin McMahon, President and Chief Executive Officer of Solx, commented, “We are very pleased to have Spotlight Innovation join the great team of investors supporting us on our journey. Their involvement validates our belief that the SOLX Gold Shunt will provide glaucoma surgeons with an important new tool for treating patients challenged by severe glaucoma.”
STLT obviously has SERIOUS UPSIDE potential here! STLT is a serious hidden gem in the BIOTECH space that is obviously making HEADLINES in their fight against ZIKA VIRUS, CANCER, SPINAL MUSCULAR ATROPHY (SMA), REFRACTORY GLAUCOMA & CHRONIC PAIN!
I mean really… This is just INSANE! A company trading below $0.60 with this much mind blowing potential + over $7M IN TOTAL ASSETS.
Did I mention that STLT hit a new 52-week high of $1.75 on November 4th…??
If STLT made a run back to $1.75 from the current trading range it would represent gains of up to +201pct!
The current gain potential on STLT is extremely rare for a company trading in the biotech space @ such undervalued levels, so start your research immediately.
About STLT
Spotlight Innovation Inc. (STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, they leverage their extensive relationships with leading scientists, academic institutions and other sources. They provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, they will endeavor to partner with proven market leaders via sale, out-license or strategic alliance.
Spotlight Innovation subsidiary Celtic Biotech Iowa is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.
CHRONIC PAIN
Spotlight Innovation subsidiary Caretta Therapeutics is developing and commercializing products—derived from cobra and rattlesnake venom—that have potential analgesic properties. Caretta Therapeutics has entered into a licensing agreement with Dr. Paul Reid for rights to develop and commercialize products derived from snake venom that may provide analgesic relief from moderate to severe chronic pain. Under the terms of the agreement, Dr. Reid has agreed to grant an exclusive, worldwide license to Caretta Therapeutics to develop, manufacture and sell the products. The products are intended to be available as over-the-counter formulations.
ZIKA VIRUS (ZIKV)
Spotlight Innovation has entered into a Sponsored Research Agreement with Florida State University (FSU) to support research directed by FSU Prof. Hengli Tang aimed at developing safe and effective drugs to treat patients infected with Zika virus. On August 29, 2016, Prof. Hengli Tang co-authored a study, published in Nature Medicine, reporting two classes of compounds: one that protects Zika virus-infected neural cells from programmed cell death (“apoptosis”) and another that directly inhibits Zika virus replication. According to the study, when used in combination, compounds from the two classes enhanced the neuroprotective effect. In March 2016, Prof. Tang co-authored a study published in Cell Stem Cell that demonstrated for the first time the ability of ZIKV to target human embryonic cortical neural progenitor cells.
Watch the video below to see Prof. Tang and his team discuss their small molecule screening program:
SPINAL MUSCULAR ATROPHY (SMA)
Spotlight Innovation has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers. Spinal Muscular Atrophy affects between 1 in 6,000 and 1 in 10,000 newborns. Approximately 1 in 40 to 1 in 50 adults have only a single intact spinal motor neuron 1 (SMN1) gene, which encodes a protein (SMN) required for proper neuromuscular function. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two.
REFRACTORY GLAUCOMA
Spotlight Innovation Inc. has made a strategic investment in Solx, Inc., a Massachusetts-based, privately-held medical device company. Solx’s lead product is the SOLX Gold Shunt™, a first-in-class, implantable drainage device designed to reduce elevated intraocular pressure (IOP) associated with refractory glaucoma without creating a bleb. The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. Approved for use in Canada and Europe, the SOLX Gold Shunt has been tested in a multi-center clinical trial, is investigational and is awaiting FDA approval in the U.S.
Zika Declared Global Health Threat (WHO)
The World Health Organization declared the Zika virus and its suspected link to birth defects an international public health emergency In February 2016, a rare move that signals the seriousness of the outbreak and gives countries new tools to fight it.
An outbreak of the Zika virus, which is transmitted by mosquitoes, was detected in Brazil in May 2014 and has since moved into more than 20 countries in Latin America, including two new ones announced Monday: Costa Rica and Jamaica.
The main worry is over the virus’s possible link to microcephaly, a condition that causes babies to be born with unusually small heads and, in the vast majority of cases, damaged brains. Reported cases of microcephaly are rising sharply in Brazil, ground zero for the disease, though researchers have yet to establish that Zika causes the condition.
North American Market To Drive Growth Spinal Muscular Atrophy (SMA)
North America dominates the global market for SMA treatment due to the high prevalence of SMA and increased adoption of SMA treatment options in the region. In addition, technological advancements in the field are driving the SMA treatment in the North America. Asia, followed by Europe, is expected to experience a high growth rate in the SMA treatment market in the next few years.
China and India are expected to be the fastest-growing SMA treatment markets in the Asian region. Some of the key driving forces for the SMA treatment market in emerging countries are: A large pool of patients and rising government initiatives in the form of funding and strict laws. In addition, increasing awareness about the diagnosis and treatment of SMA is driving the market in the Asia region.
STLT could Provide Traders With Significant Short-Term Gains on Tuesday 12/06!
Based on the fact; The 20 MA is $0.7742, currently above current valuation, opening the door for short-term upside of up to +33pct.
STLT obviously has SERIOUS UPSIDE potential here! STLT is a serious hidden gem in the BIOTECH space that is obviously making HEADLINES in their fight against ZIKA VIRUS, CANCER, SPINAL MUSCULAR ATROPHY (SMA), REFRACTORY GLAUCOMA & CHRONIC PAIN!
I mean really… This is just INSANE! A company trading below $0.60 with this much mind blowing potential + over $7M IN TOTAL ASSETS.
Did I mention that STLT hit a new 52-week high of $1.75 on November 4th…??
____________
Start your research and due diligence right now on my…
Brand New Short-Term Day/Swing Trade Alert **STLT**
P.S. – My track record this year has been seriously awesome! Just take a look at some of my biggest verified winning trade ideas below:
My Top Trade Alerts Of 2016
9/1/16 – (SMCE) Ran From .0248 to .035 = +41pct
9/6/16 – (DCLT) Ran From .0028 to .013 = +364pct
9/13/16 – (FLCR) Ran From .0016 to .0065 = +306pct
9/20/16 – (QPRC) Ran From .0022 to .006 = +172pct
9/23/16 – (BLGA) Ran From .0079 to .0155 = +96pct
9/27/16 – (PSNX) Ran From .0089 to .014 = +57pct
9/30/16 – (CORMF) Ran From .4601 to .558 = +21pct
10/04/16 – (AOXY) Ran From .05 to .11 = +120pct
10/07/16 – (ELRN) Ran From .01 to .0425 = +325pct
10/10/16 – (UNDT) Ran From .02 to .145 = +625pct
10/13/16 – (PLLX) Ran From .0388 to .1529 = +294pct
10/18/16 – (ABBY) Ran From .004 to .01534 = +283pct
10/21/16 – (EMAV) Ran From .005 to .0606 = +1112pct
10/25/16 – (ACNV) Ran From .007 to .018 = +157pct
10/27/16 – (NSEH) Ran From .012 to .0299 = +149pct
11/04/16 – (JFIL) Ran From .014 to .0375 = +167pct
11/09/16 – (CGYG) Ran From .03 to .06 = +100pct
11/18/16 – (DTST) Ran From .05995 to .13 = +116pct
11/28/16 – (IEGH) Ran From 5.00 to 5.95 = +19pct
12/02/16 – (KSIX) Ran From .36 to .48 = +33pct
These Percentage Runs Are Based From The Open To HOD
Make sure to always do your own research and due diligence on any day and swing trade alert I bring to your attention. I am not a licensed financial advisor.
Read Full Disclaimer
Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99pct of the time all that matters is how it trades. If a company doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book gains quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the company is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book gains quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions)
Pursuant to an agreement between SmallCapFirm and Sunrise Media, LLC (a non affiliated 3rd party), SmallCapFirm has been hired for a period beginning on 12/05/16 and ending on 12/06/16 to publicly disseminate information about (STLT) via Website, Email and SMS. We have been paid five thousand five hundred USD via bank wire transfer. We own zero shares of (STLT).
SmallCapFirm’s full disclaimer is to be read and fully understood before using SmallCapFirm’s website, or joining SmallCapFirm’s email or text list. By viewing SmallCapFirm’s website and/or reading SmallCapFirm’s email or text newsletter you are agreeing to SmallCapFirm’s full disclaimer which can be read at:
